Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Many drug companies have conceded that the days of super-sized price increases, which sometimes occurred multiple times per year, are gone for now. President Trump's rhetoric around price controls and public outrage over high drug costs have forced the industry to soften, as it heavily lobbies politicians behind the scenes.
So does that mean the drug industry will lose a lot of money? Not really. First-quarter reports show many of the largest pharmaceutical companies increased their profits compared with the same period last year. Sales of some drugs lagged, but companies still hiked list prices by high single digits — well above general inflation.
A handful of major pharmaceutical firms reported higher first-quarter earnings this week. Part of that was due to cutting back on operating expenses, like research and marketing, but list prices were also raised for many drugs.
- Amgen: Profit jumped 9%, surpassing $2 billion, even though sales declined. Amgen raised the list price of its major rheumatoid arthritis drug Enbrel by 8.4% in January, according to data obtained by Axios, as a way to offset competing drugs.
- AbbVie: Profit soared 26%. Arthritis blockbuster drug Humira, which got an 8.4% list price boost in January, continues to be the company's biggest earner.
- Bristol-Myers Squibb: A 32% jolt to earnings came thanks to big sales of cancer drug Opdivo.
- Celgene: First-quarter profit almost hit $1 billion as demand for multiple myeloma drug Revlimid took off. Celgene raised the list price of Revlimid by 8% in January.
- Biogen: Sales of its multiple sclerosis drug Tecfidera basically stayed the same despite an 8% price hike in January. Biogen's profit declined, but it was still around three-quarters of a billion dollars.
- Eli Lilly: Lost money due to severance and acquisition costs, not because people weren't buying their drugs.